Abstract
Mass vaccination campaigns are essential to control the ongoing novel severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) pandemic. The Covishield vaccine consists of the replication-deficient simian adenovirus vector ChAdOx1, which contains the full-length structural spike protein of SARS-CoV-2. Occasionally, it can lead to cutaneous reactions that contribute to fear of vaccination, hesitancy, and incomplete vaccination schedules. We report a case of facial angioedema following the first dose of Covishield in a 63-year-old woman with no previous history of allergies or hypersensitivity to drugs or vaccines. No rebound of angioedema was recorded after the second homologous and third heterologous doses.
【초록키워드】 SARS-CoV-2, Vaccine, coronavirus, vaccination, pandemic, Vaccines, drug, Spike protein, allergy, homologous, ChAdOx1, Heterologous, hypersensitivity, acute respiratory syndrome, reaction, mass, first dose, doses, full-length, contribute, facial, simian adenovirus vector, was recorded, 【제목키워드】 coronavirus, Follow-up, booster dose, Angioedema, acute respiratory syndrome, first dose,